GPBB Biomarker Detection via Specific Oligo-Peptide Antibodies

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for detecting glycogen phosphorylase isoenzyme BB (GPBB) in patient samples are not sufficiently precise for early diagnosis of myocardial infarction, strokes, and preeclampsia.

Innovation Solution

The use of specific oligo-peptide sequences such as RDHLVGRWIR, IRRFKSSKFGCR, RHLEIIYAINQR, LIIKLVT, and VVGDRLKVIF, or combinations thereof, to develop detecting agents that recognize and bind specifically to GPBB epitopes, enabling quantitative detection in patient samples.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If standard clinic diagnosis methods using troponin and CK-MB are used, then diagnostic reliability is improved, but early detection capability deteriorates because these markers are detectable only after 4-6 hours of coronary occlusion

Engineering Contradiction:

Improvediagnostic reliabilityVSAvoidearly detection time

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent extracts and isolates the GPBB isoenzyme specifically from the glycogen phosphorylase enzyme system. By using antibodies that selectively bind to GPBB rather than the parent enzyme or other isoenzymes, the method extracts the specific diagnostic signal needed for early myocardial infarction detection, achieving both early detection capability and diagnostic reliability

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent changes the diagnostic parameter from traditional markers like troponin and CK-MB to GPBB levels in serum. This parameter change enables detection within hours of symptom onset rather than waiting 4-6 hours, while maintaining diagnostic reliability through specific antibody binding to GPBB epitopes

Inventive Principle:

Principle #35Parameter changes

2Productivity

If point-of-care assays measuring serum cardiac troponin T are used, then analysis time is reduced and sample transport is saved, but early laboratory diagnosis satisfaction deteriorates

Engineering Contradiction:

Improveanalysis speedVSAvoidearly diagnosis accuracy

Core Design Contradiction:

ProductivityVSMeasurement precision

Solution Approach 1:

The patent changes the measured parameter from troponin T to GPBB levels in serum. GPBB appears earlier in the clinical course of myocardial infarction, allowing point-of-care assays to achieve both rapid analysis and accurate early diagnosis by detecting this different biomarker parameter

Inventive Principle:

Principle #35Parameter changes

3Adaptability or versatility

If detecting agents with broad specificity are used, then detection versatility is improved, but measurement precision for GPBB deteriorates due to cross-reactivity with other glycogen phosphorylase isoenzymes

Engineering Contradiction:

Improvedetection rangeVSAvoidGPBB detection accuracy

Core Design Contradiction:

Adaptability or versatilityVSMeasurement precision

Solution Approach 1:

The patent applies local quality by designing antibodies with highly specific binding characteristics targeted at particular epitopes of GPBB. Instead of broad specificity, the detecting agents have localized, precise recognition sites that bind only to GPBB and not to other glycogen phosphorylase isoenzymes like GPLL or GPMM, eliminating cross-reactivity while maintaining detection precision

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent segments the glycogen phosphorylase enzyme system by specifically targeting the BB isoenzyme subset. The detecting agents are designed to recognize and bind only to GPBB, separating it from other isoenzymes, thereby achieving measurement precision through selective segmentation of the target analyte

Inventive Principle:

Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The described detecting agents allow for precise quantitative determination of GPBB levels in patient samples, facilitating early and accurate diagnosis of myocardial infarction, strokes, and preeclampsia.

Implementation Method 1

A detecting agent for specific detecting glycogen phosphorylase isoenzyme BB (GPBB), wherein the detecting agent is characterized by specific recognizing and binding to an epitope of the GPBB

Methodology Applied

Scientific EffectAntibody-antigen binding:

Data Source

PatentUS20250044290A1Biomarkers For Detecting Human Glycogen Phosphorylase Isoenzyme BB

Publication Date: 2025.02.06 DIAGENICS GRP INC

AI summary

Described are an oligo-peptide sequence of any of RDHLVGRWIR (E1), IRRFKSSKFGCR (E2), RHLEIIYAINQR (E3), LIIKLVT (E4), VVGDRLKVIF (E5), any combination of E1 to E3; or combination of E4 and E5. Further described is a detecting agent for specific detecting glycogen phosphorylase iso-enzyme BB (GPBB), wherein the detecting agent is characterized by specific recognizing and binding to (1) an epitope of the GPBB comprising an oligo-peptide sequence of any of RDHLVGRWIR (E1), IRRFKSSKFGCR (E2), RHLEIIYAINQR (E3) or any combination of E1 to E3; or (2) an epitope of GPBB comprising an oligo-peptide sequence of LIIKLVT (E4), and/or VVGDRLKVIF (E5), or combination of E4 and E5.